Mangalam Drugs & Organics Valuation

Is 532637 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 532637 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 532637's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 532637's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532637?

Key metric: As 532637 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 532637. This is calculated by dividing 532637's market cap by their current earnings.
What is 532637's PE Ratio?
PE Ratio	18x
Earnings	₹94.03m
Market Cap	₹1.69b

532637 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.7x
Enterprise Value/EBITDA	9.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 532637's PE Ratio compare to its peers?

The above table shows the PE ratio for 532637 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	21.7x
524412 Aarey Drugs & Pharmaceuticals	27x	n/a	₹1.6b
QUESTLAB Quest Laboratories	15.5x	n/a	₹1.8b
SOTAC Sotac Pharmaceuticals	29.1x	n/a	₹1.3b
532384 Tyche Industries	15.4x	n/a	₹2.0b
532637 Mangalam Drugs & Organics	18x	n/a	₹1.7b

Price-To-Earnings vs Peers: 532637 is good value based on its Price-To-Earnings Ratio (18x) compared to the peer average (21.7x).

Price to Earnings Ratio vs Industry

How does 532637's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$70.43m
524652 Ind-Swift	2x	n/a	US$13.12m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 532637 is good value based on its Price-To-Earnings Ratio (18x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is 532637's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532637 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	18x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 532637's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Colinz Laboratories

₹138.6m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹55.02

-8.8%

33.1%